Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200 Day Moving Average – Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.35 and traded as high as $3.95. Cumberland Pharmaceuticals shares last traded at $3.88, with a volume of 122,573 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CPIX shares. Wall Street Zen upgraded Cumberland Pharmaceuticals to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Up 2.4%

The company has a market cap of $58.04 million, a PE ratio of -16.17 and a beta of -0.52. The company has a fifty day moving average of $4.00 and a two-hundred day moving average of $3.35. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23.

Institutional Trading of Cumberland Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CPIX. Dimensional Fund Advisors LP lifted its stake in Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after buying an additional 4,200 shares during the period. Geode Capital Management LLC lifted its stake in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 5,653 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth approximately $192,000. Finally, Two Sigma Investments LP boosted its holdings in Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the period. 15.51% of the stock is owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.